AHA 2025 Clinical Insights: Advancing Cardiology Care
Explore concise, expert-led educational activities delivering the latest updates from AHA 2025. Dive into key developments across atrial fibrillation, heart failure, lipid management, and aortic stenosis. Find out how breakthrough science is translating into practical clinical impact.
Episodes 1-14 of 14
Highlights of the Latest Hypertension Guidelines
CardiologyHighlights of the Latest Hypertension Guidelines
Clinical Perspective on New Therapies in Resistant Hypertension
CardiologyClinical Perspective on New Therapies in Resistant Hypertension
Precision Medicine in Obstructive HCM Care: The Promise of Cardiac Myosin Inhibitors
CardiologyPrecision Medicine in Obstructive HCM Care: The Promise of Cardiac Myosin Inhibitors
The Lp(a)-Lowering Landscape: Navigating Current and Future Therapeutic Options
CardiologyThe Lp(a)-Lowering Landscape: Navigating Current and Future Therapeutic Options
DARE AF Trial: Dapagliflozin to Reduce AF Burden After Catheter Ablation in Patients Without Diabetes or Heart Failure
CardiologyDARE AF Trial: Dapagliflozin to Reduce AF Burden After Catheter Ablation in Patients Without Diabetes or Heart Failure
DECAF Trial: Does Eliminating Coffee Reduce Atrial Fibrillation Recurrence in Symptomatic Patients?
CardiologyDECAF Trial: Does Eliminating Coffee Reduce Atrial Fibrillation Recurrence in Symptomatic Patients?
- advertisement
POLY HF Trial: A Polypill Strategy for Heart Failure With Reduced Ejection Fraction (HFrEF)
CardiologyPOLY HF Trial: A Polypill Strategy for Heart Failure With Reduced Ejection Fraction (HFrEF)
The LDL-C-Lowering Landscape: Navigating Current and Future Therapeutic Options
CardiologyThe LDL-C-Lowering Landscape: Navigating Current and Future Therapeutic Options
ADAPT AF-DES: Antithrombotic Strategies Beyond 12 Months for Patients With AF Treated With Drug-Eluting-Stents
CardiologyADAPT AF-DES: Antithrombotic Strategies Beyond 12 Months for Patients With AF Treated With Drug-Eluting-Stents
OCEAN Trial at AHA 2025: Anticoagulation After AF Ablation in High-Risk Patients
CardiologyOCEAN Trial at AHA 2025: Anticoagulation After AF Ablation in High-Risk Patients
Primary Results of the VESALIUS-CV Trial: Evolocumab in Patients at High Cardiovascular Risk Without Prior MI or Stroke
CardiologyPrimary Results of the VESALIUS-CV Trial: Evolocumab in Patients at High Cardiovascular Risk Without Prior MI or Stroke
Real-World Impact of Evolocumab on MACE Reduction in ASCVD
CardiologyReal-World Impact of Evolocumab on MACE Reduction in ASCVD
- advertisement
Global Burden of Stroke and Myocardial Infarction in Patients at High Risk of First MACE: Insights From the VESALIUS-REAL Study
CardiologyGlobal Burden of Stroke and Myocardial Infarction in Patients at High Risk of First MACE: Insights From the VESALIUS-REAL Study
Evolocumab in Patients at High Cardiovascular Risk Without Prior MI or Stroke: Primary Results of the VESALIUS-CV Trial
CardiologyEvolocumab in Patients at High Cardiovascular Risk Without Prior MI or Stroke: Primary Results of the VESALIUS-CV Trial
